Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Victoza (liraglutide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
• This summary is based on the review of 48 systematic review(s)/meta-analysis(es). ^[1-48]
• Cardiac Function in Type 2 Diabetes: Liraglutide significantly enhanced Left Ventricular Ejection Fraction (SMD = -0.38, 95% CI [-0.70, -0.06], P = .02) and improved the Cardiac Index (SMD = -1.05, 95% CI [-1.52, -0.59], P < .0001), Stroke Volume (SMD = -0.67, 95% CI [-1.02, -0.32], P = .0002), and Early Diastolic Filling Velocity/Late Atrial Filling Velocity Ratio (SMD = -0.52, 95% CI [-0.82, -0.22], P = .0006).
• Glycemic Control and Non-Glycemic Efficacy in Type 2 Diabetes: IDegLira (Insulin Degludec/Liraglutide) showed reductions in Glycated Hemoglobin (HbA1c) (WMD 0.52%, 95% CI 0.33%-0.71%), Fasting Blood Glucose (0.32 mg/dL, 0.14-0.50 mg/dL), and Plasma Glucose (0.25 mmol/L, 0.25-0.36 mmol/L). Non-glycemic outcomes included decreased systolic blood pressure and elevated heart rate.
• Weight Loss in Obese/Overweight Adults: Liraglutide 3.0 mg once daily resulted in 65.3% of participants achieving at least 5% weight loss and 30.7% achieving at least 10% weight loss. Semaglutide 2.4 mg once weekly resulted in 86.6% achieving at least 5% weight loss and 75.3% achieving at least 10% weight loss.
• Cardiovascular Outcomes in Type 2 Diabetes: GLP-1RAs, including liraglutide, reduced the risk of Major Adverse Cardiac Events (MACE) (HR 0.72, 95% CI 0.65 - 0.93), hospitalization due to heart failure (HR 0.84, 95% CI 0.77 - 0.91), stroke (HR 0.86, 95% CI 0.75 - 0.98), and all-cause mortality (HR 0.82, 95% CI 0.76 - 0.88).
• Cardiac Function in Type 2 Diabetes (Liraglutide): The safety section indicates a favorable impact on cardiac function, though the evidence quality was rated as low and very low.
• Safety Profile of IDegLira: There was no significant association with hypoglycemia or nocturnal hypoglycemia.
• Adverse Effects in Obese/Overweight Adults (Liraglutide and Semaglutide): Comparable frequency of mild to moderate adverse events between treatment and control groups; discontinuation rates ranged from 2.4% to 11.4% for Liraglutide and 0.7% to 8.6% for the control group.
• There is no population-type or subgroup information available in the reviewed studies.